Wednesday, May 15, 2019
Home »
» Medical News Today: Novel Alzheimer's drug passes first phase of human testing
Medical News Today: Novel Alzheimer's drug passes first phase of human testing
A drug that tackles toxic protein buildup in Alzheimer's disease in a novel way has passed phase 1 of clinical trials, which tests safety in humans.
Related Posts:
Eight suicides in a month make for 'mental health crisis' in PIke Pike County (Wikipedia map) By Stan Ingold, WEKU Officials in Eastern Kentucky are dealing with what they are calling a “mental health crisis.” In Pike County, over the last 30 days at least eight people have commit… Read More
Lottery system will determine who gets 48 licenses for retailers and 10 for processors of medical cannabis in 11 Kentucky regionsBy Melissa Patrick Kentucky Health News Gov. Andy Beshear gave an update on the medical cannabis licensing program Thursday, after signing this year's medical cannabis bill into law the day before. "We have worked hard to c… Read More
Louisville's Norton Healthcare receives $20 million gift to support Parkinson's disease programming and research Norton Healthcare has received a $20 million gift for the "Just Imagine" campaign to support programing and research in Parkinson's disease and movement disorders at the Norton Neuroscience Institute. The Jus… Read More
Free webinar, Health for a Change: Tackling the Immunization Crisis, is scheduled for Wednesday, May 8, by health foundation The Foundation for a Healthy Kentucky's next "Health for a Change" webinar is titled "Tackling the Immunization Crisis." It will be held Wednesday, May 8, from 11 a.m. to noon ET. The free event will address three mai… Read More
Top senators, one of whom lost both parents to smoking, say no advocates spoke to them about increasing anti-tobacco spendingBy Al Cross Kentucky Health News Kentucky's top two state senators said Tuesday that none of the advocates for more funding of tobacco prevention spoke to them about it during the legislative session that ended Monday night. … Read More
0 comments:
Post a Comment